Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (HIMS)
NYSE:HIMS
Holding HIMS?
Track your performance easily
HIMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.51 - $30.44
Previous Close$23.53
Volume14.72M
Average Volume (3M)13.16M
Market Cap
$4.72B
Enterprise Value$4.90B
Total Cash (Recent Filing)$254.07M
Total Debt (Recent Filing)$11.36M
Price to Earnings (P/E)54.4
Beta2.40
Next Earnings
Mar 03, 2025EPS Estimate
$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding218,479,114
10 Day Avg. Volume28,565,562
30 Day Avg. Volume13,163,350
Standard Deviation0.20
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)11.71
Price to Sales (P/S)3.40
Price to Cash Flow (P/CF)13.50
P/FCF Ratio14.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.94
Enterprise Value/Gross Profit6.85
Enterprise Value/Ebitda41.03
Forecast
1Y Price Target
$24.00Price Target Upside11.16% Upside
Rating ConsensusHold
Number of Analyst Covering12
Hims & Hers Health News
Bulls Say, Bears Say
Bulls Say
Business Model SuccessHIMS has a tested and regulatory compliant business model that has driven clear success.
Personalization And GrowthHIMS is personalizing patient care across specialties, and HIMS' ability to customize offerings at scale is difficult to replicate.
Subscriber Growth And RetentionSolid retention among GLP-1 subscribers, with 85% and 70% retention for its offering for 4 weeks and 12 weeks durations, respectively, shows stronger retention compared to branded medications.
Bears Say
CompetitionAmazon's entrance into these markets signal growing competition for customers and is expected to impact the prices that HIMS can charge, HIMS’ ability to grow and capture new customers, and HIMS’ LTV/CAC.
Market VolatilityThe stock is bound to see continued volatility both to the upside and downside on headlines tied to the overall supply availability of all things GLP-1s-related, whether it is tied to products that HIMS sells or not.
Regulatory ChallengesThe regulatory overhang for semaglutide remains a key uncertainty, with concerns about the long-term duration of GLP-1 sales and how they factor into the enterprise growth profile.
---
Ownership Overview
10.47% Insiders
16.38% Mutual Funds
12.44% Other Institutional Investors
38.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Hims & Hers Health
Desktop Users
Mobile Users
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $7.50 and its highest was $30.44 in the past 12 months.
What is Hims & Hers Health’s market cap?
Currently, no data Available
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Mar 03, 2025 which is in 103 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Nov 04, 2024. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.111 by $0.209.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is $0.18.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 210,101,490 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of $0.32 in its last earnings report, beating expectations of $0.111. Following the earnings report the stock price went down -0.578%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Among the largest hedge funds holding Hims & Hers Health’s share is Royce & Associates LLC. It holds Hims & Hers Health’s shares valued at 6M.
---
Hims & Hers Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$24.00 (11.16% Upside)
$24.00 (11.16% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 84%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 49.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 21.4%
Last 30 Days ▲ 21.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
214.99%
12-Months-Change
Fundamentals
Return on Equity
26.35%
Trailing 12-Months
Asset Growth
45.52%
Trailing 12-Months
Company Description
Hims & Hers Health
Oaktree Acquisition Corp. is an emerging growth company, which engages in the provision of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Patrick McCaney, Alexander Taubman and Mathew Pendo in 2019 and is headquartered in Los Angeles, CA.
---
HIMS Earnings Call
Q3 2024
0:00 / 0:00
---
HIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
---
HIMS Stock 12 Month Forecast
Average Price Target
$24.00
▲(11.16% Upside)
Technical Analysis
Best Analysts Covering HIMS
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+119.79%
reiterated a buy rating 21 hours ago
Copying Jonna Kim's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +119.79% per trade.
---